Circulating parasite antigen in patients with hydrocephalus secondary to neurocysticercosis

被引:36
作者
Garcia, HH
Gonzalez, AE
Gilman, RH
Bernal, T
Rodriguez, S
Pretell, EJ
Azcurra, O
Parkhouse, RME
Tsang, VCW
Harrison, LJS
机构
[1] Univ Peruana Cayetano Heredia, Dept Microbiol, Lima, Peru
[2] Univ Peruana Cayetano Heredia, Dept Pathol, Lima, Peru
[3] Univ Nacl Mayor San Marcos, Sch Vet Sci, Lima, Peru
[4] Inst Nacl Ciencias Neurol, Dept Transmissible Dis, Lima, Peru
[5] Gulbenkian Inst Sci, P-2780 Oeiras, Portugal
[6] Ctr Dis Control, Parasit Dis Branch, Atlanta, GA 30333 USA
[7] Univ Edinburgh, Dept Trop Anim Hlth, Sir Alexander Robertson Ctr Trop Vet Med, Easter Bush Vet Ctr, Roslin EH25 9RG, Midlothian, Scotland
[8] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA
关键词
D O I
10.4269/ajtmh.2002.66.427
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
End stages of neurocysticercosis include residual intraparenchymal brain calcifications and hydrocephalus. Although brain calcifications alone have a benign prognosis, hydrocephalus is frequently associated with chronic inflammation and intracranial hypertension, together with a protracted clinical evolution, and may lead to patient deaths. By using a monoclonal-based antigen detection enzyme-linked immunosorbent assay, we measured the levels of circulating parasite antigen in the sera of 56 patients with neurocysticercosis: 27 with calcifications only and 29 with hydrocephalus. The assay gave positive results in 14 of 29 patients with hydrocephalus but was consistently negative in patients with calcifications. Circulating parasite antigen in hydrocephalus secondary to neurocysticercosis indicates the presence of live parasites in these patients and thus a potential benefit from antiparasitic therapy.
引用
收藏
页码:427 / 430
页数:4
相关论文
共 34 条
[11]   A PROGNOSTIC CLASSIFICATION OF CEREBRAL CYSTICERCOSIS - THERAPEUTIC IMPLICATIONS [J].
ESTANOL, B ;
CORONA, T ;
ABAD, P .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1986, 49 (10) :1131-1134
[12]   Controversies in the management of cysticercosis [J].
Evans, C ;
Garcia, HH ;
Gilman, RH ;
Friedland, JS .
EMERGING INFECTIOUS DISEASES, 1997, 3 (03) :403-405
[13]   DISCREPANCIES BETWEEN CEREBRAL COMPUTED-TOMOGRAPHY AND WESTERN-BLOT IN THE DIAGNOSIS OF NEUROCYSTICERCOSIS [J].
GARCIA, HH ;
HERRERA, G ;
GILMAN, RH ;
TSANG, VCW ;
PILCHER, JB ;
DIAZ, JF ;
CANDY, EJ ;
MIRANDA, E ;
NARANJO, J ;
TORRES, P ;
GALLO, C ;
CARCAMO, C ;
VERASTEGUI, M ;
MONTENEGRO, T ;
ALVAREZ, M ;
EVANS, C ;
GONZALES, AE ;
CASTRO, M ;
MARTINEZ, M ;
PORRAS, M ;
ALVARADO, M ;
ORRILLO, E ;
PALOMINO, L ;
ALBAN, G ;
CALAGUA, L ;
ESCALANTE, S ;
TRELLES, L ;
ALIAGA, O ;
RIOSSAAVEDRA, N ;
VELARDE, M ;
CUBA, JM ;
ESTRADA, H ;
SOTO, M ;
PORTILLA, L ;
TERASHIMA, A ;
CABRERA, J ;
CAMPOS, P ;
MOROTE, D ;
ROCCA, U .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1994, 50 (02) :152-157
[14]   Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients [J].
Garcia, HH ;
Parkhouse, RME ;
Gilman, RH ;
Montenegro, T ;
Bernal, T ;
Martinez, SM ;
Gonzalez, AE ;
Tsang, VCW ;
Harrison, LJS .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2000, 94 (06) :673-676
[15]   A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis [J].
Garcia, HH ;
Harrison, LJS ;
Parkhouse, RME ;
Montenegro, T ;
Martinez, SM ;
Tsang, VCW ;
Gilman, RH .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1998, 92 (04) :411-414
[16]   Serologic evolution of neurocysticercosis patients after antiparasitic therapy [J].
Garcia, HH ;
Gilman, RH ;
Catacora, M ;
Verastegui, M ;
Gonzalez, AE ;
Tsang, VCW ;
Martinez, M ;
Altamirano, J ;
Trelles, L ;
Cuba, JM ;
Alvarado, M ;
Alban, G ;
Estrada, H ;
RiosSaavedra, N ;
Soto, M ;
Torres, MP ;
Boero, J ;
Gavidia, C ;
Barron, E ;
Falcon, N ;
Lopez, MT ;
Pilcher, JB ;
Evans, C ;
Herrera, G ;
Terashima, A ;
Campos, P ;
Cabrera, J ;
Rocca, U .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (02) :486-489
[17]   Albendazole therapy for neurocysticercosis: A prospective double-blind trial comparing 7 versus 14 days of treatment [J].
Garcia, HH ;
Gilman, RH ;
Horton, J ;
Martinez, M ;
Herrera, G ;
Altamirano, J ;
Cuba, JM ;
RiosSaavedra, N ;
Verastegui, M ;
Boero, J ;
Gonzalez, AE ;
Alvarado, M ;
Orrillo, E ;
Trelles, L ;
Escalante, S ;
Palomino, L ;
Alban, G ;
Estrada, H ;
Velarde, M ;
Garate, E ;
Martinez, H ;
Soto, M ;
Catacora, M ;
Guerron, A ;
Romani, C ;
Diaz, F ;
Torres, MP ;
Gavidia, C ;
Barron, E ;
Falcon, N ;
Lopez, MT ;
Tsang, VCW ;
Pilcher, JB ;
Rivara, A ;
Terashima, A ;
Campos, P ;
Cabrera, J ;
Rocca, U .
NEUROLOGY, 1997, 48 (05) :1421-1427
[18]   Taenia solium cysticercosis [J].
Garcia, HH ;
Del Brutto, OH .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2000, 14 (01) :97-+
[19]  
GARCIA HH, 1999, T SOLIUM TAENIASIS C
[20]   Prevalence of taeniosis among patients with neurocysticercosis is related to severity of infection [J].
Gilman, RH ;
Del Brutto, OH ;
García, HH ;
Martínez, M .
NEUROLOGY, 2000, 55 (07) :1062-1062